Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Blood Cancer Journal|April 4, 2026
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapyMasooma Shifa Rana, Sebastian Fernandez-Pol, Alexandria Jensen, et al.
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Blood|July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple MyelomaHitomi Hosoya, Arash Velayati, Danai Dima, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2015
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3Ahmad Salameh, Alessandro K Lee, Marina Cardó-Vila, et al.
Blood|July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemiaHrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Haematologica|July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myelomaDanai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Cancer Cell|December 30, 2022
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasBrian J Sworder, David M Kurtz, Stefan K Alig, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Pageof 4